Assembly Biosciences vs Viridian Therapeutics, Inc.\de
Assembly Biosciences and Viridian Therapeutics, Inc.\de are similar in size: $72.3m and $70.8m of revenue in their latest fiscal years. Viridian Therapeutics, Inc.\de grew faster (23359.9% against 153.5%). Assembly Biosciences kept more of each dollar of sales as profit: a net margin of -8.5% against -483.6%. Assembly Biosciences carries less debt relative to equity (0.0% against 6.9%).
| Latest fiscal year | Assembly BiosciencesASMB, 2025 | Viridian Therapeutics, Inc.\deVRDN, 2025 |
|---|---|---|
| Revenue | $72.3m | $70.8m |
| Revenue growth | 153.5% | 23359.9% |
| Net income | −$6.1m | −$343m |
| Operating margin | -16.8% | -512.9% |
| Net margin | -8.5% | -483.6% |
| Return on equity | -5.1% | -49.2% |
| Free cash flow | −$41.2m | −$277m |
| Cash | $58.5m | $212m |
| Total debt | $0 | $49.9m |
| Debt to equity | 0.0% | 6.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 252 |
| Market value | $392m | $2.85bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 5 sales | 1 buys, 3 sales |